AstraZeneca PLC (LON:AZN) Gained Better Natixis Rating; Iridium Communications (IRDM) Sentiment Is 1.33

September 6, 2017 - By Winifred Garcia

In a analysts note revealed to clients today, Natixis upgraded shares of AstraZeneca PLC (LON:AZN) to a “Buy” rating. The firm currently has a GBX 5738.00 target price per share on the stock. Natixis’s target price per share gives a potential upside of 26.30% from the stock’s previous close.

Iridium Communications Inc. is engaged in providing global satellite communications services and products. The company has market cap of $1.05 billion. The Firm offers mobile voice and data communications services through satellite, and provides communications services offering true global coverage. It has a 12.32 P/E ratio. It provides services to businesses, the United States and foreign governments, non-governmental organizations and clients through its satellite network, which has over 70 in-orbit satellites with in orbit spares and related ground infrastructure.

Irving Magee Investment Management holds 2.14% of its portfolio in Iridium Communications Inc for 573,120 shares. Van Berkom & Associates Inc. owns 5.05 million shares or 1.95% of their US portfolio. Moreover, Knott David M has 1.63% invested in the company for 338,000 shares. The New York-based Capital Management Associates Ny has invested 1.6% in the stock. Wealthtrust Axiom Llc, a Pennsylvania-based fund reported 392,290 shares.

It closed at $10.8 lastly. It is down 20.17% since September 6, 2016 and is uptrending. It has outperformed by 3.47% the S&P500.

About 573,239 shares traded. AstraZeneca plc (LON:AZN) has 0.00% since September 6, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 31 analysts covering AstraZeneca PLC (LON:AZN), 16 have Buy rating, 3 Sell and 12 Hold. Therefore 52% are positive. AstraZeneca PLC has GBX 7600 highest and GBX 4.57 lowest target. GBX 4717.29’s average target is 3.46% above currents GBX 4559.5 stock price. AstraZeneca PLC had 528 analyst reports since July 23, 2015 according to SRatingsIntel. The stock has “Buy” rating by Liberum Capital on Thursday, July 27. The firm has “Sell” rating given on Thursday, January 28 by Pareto Securities. The stock of AstraZeneca plc (LON:AZN) has “Sell” rating given on Thursday, May 4 by Shore Capital. Morgan Stanley maintained AstraZeneca plc (LON:AZN) rating on Friday, October 2. Morgan Stanley has “Underwt/In-Line” rating and GBX 4300 target. The firm earned “Neutral” rating on Monday, February 27 by BNP Paribas. The rating was maintained by Citigroup with “Buy” on Wednesday, September 23. JP Morgan maintained the stock with “Neutral” rating in Tuesday, May 3 report. The rating was maintained by Jefferies on Friday, November 11 with “Buy”. The stock of AstraZeneca plc (LON:AZN) has “Neutral” rating given on Monday, June 5 by JP Morgan. On Tuesday, March 1 the stock rating was maintained by Barclays Capital with “Equal Weight”.

AstraZeneca PLC is a biopharmaceutical company. The company has market cap of 57.28 billion GBP. The Firm focuses on discovery and development of products, which are then manufactured, marketed and sold. It has a 19.44 P/E ratio. The Firm focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.